Geode Capital Management LLC raised its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 8.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 367,230 shares of the biopharmaceutical company’s stock after buying an additional 27,099 shares during the period. Geode Capital Management LLC owned about 0.79% of Xencor worth $8,783,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Airain ltd acquired a new position in Xencor during the first quarter worth $213,000. Algert Global LLC acquired a new position in Xencor during the first quarter worth $284,000. Clinton Group Inc. raised its position in Xencor by 4.6% in the first quarter. Clinton Group Inc. now owns 15,987 shares of the biopharmaceutical company’s stock worth $382,000 after buying an additional 700 shares in the last quarter. Tocqueville Asset Management L.P. acquired a new position in Xencor during the first quarter worth $388,000. Finally, American International Group Inc. raised its position in Xencor by 18.0% in the first quarter. American International Group Inc. now owns 21,824 shares of the biopharmaceutical company’s stock worth $522,000 after buying an additional 3,332 shares in the last quarter. Institutional investors and hedge funds own 73.53% of the company’s stock.
Xencor, Inc. (NASDAQ XNCR) opened at 19.94 on Friday. Xencor, Inc. has a 52-week low of $18.45 and a 52-week high of $29.38. The stock’s 50 day moving average is $22.56 and its 200-day moving average is $23.00. The stock’s market capitalization is $935.70 million.
Xencor (NASDAQ:XNCR) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. The company had revenue of $13.34 million during the quarter, compared to analysts’ expectations of $8.15 million. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%. Equities research analysts anticipate that Xencor, Inc. will post ($1.17) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was reported by BNB Daily and is owned by of BNB Daily. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/xencor-inc-xncr-stake-boosted-by-geode-capital-management-llc-updated-updated.html.
A number of research firms recently weighed in on XNCR. Canaccord Genuity reiterated a “buy” rating and issued a $36.00 price objective on shares of Xencor in a research note on Tuesday, August 8th. BidaskClub lowered shares of Xencor from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Zacks Investment Research lowered shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Finally, Wedbush reiterated an “outperform” rating and issued a $29.00 price objective on shares of Xencor in a research note on Friday, June 16th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $29.33.
In other Xencor news, Director Bruce L. A. Carter sold 20,000 shares of Xencor stock in a transaction on Wednesday, June 14th. The shares were sold at an average price of $20.61, for a total value of $412,200.00. Following the completion of the transaction, the director now directly owns 48,880 shares of the company’s stock, valued at approximately $1,007,416.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bruce L. A. Carter sold 12,400 shares of Xencor stock in a transaction on Friday, May 26th. The stock was sold at an average price of $22.19, for a total transaction of $275,156.00. Following the completion of the transaction, the director now directly owns 83,344 shares of the company’s stock, valued at $1,849,403.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have purchased 182,035 shares of company stock valued at $3,728,456 and have sold 34,766 shares valued at $739,408. Company insiders own 4.03% of the company’s stock.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.